ArticleImmunology2026
Inducing Antigen-Specific and Functional Immune Responses in Mice Toward Bovine Herpesvirus 1 and Bovine Respiratory Syncytial Virus by Chimeric Peptides Delivered by Bovine Herpesvirus 4-Based Vector.
Article in Immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Bovine respiratory disease (BRD) remains a major health and economic challenge for the cattle industry, driven by the interplay of viral and bacterial pathogens that compromise animal welfare, productivity and antimicrobial stewardship. Among the primary viral agents, Bovine herpesvirus 1 (BoHV-1) and Bovine respiratory syncytial virus (BRSV) play critical roles in initiating and exacerbating respiratory pathology. In this study, we engineered two recombinant Bovine herpesvirus 4 (BoHV-4)-based vectors encoding chimeric antigens based on BoHV-1 glycoprotein D (gD) and BRSV fusion glycoprotein (gF), with the goal of developing a multivalent vaccine platform. Immunological evaluation in a murine model demonstrated that both vaccine constructs elicited robust humoral and cell-mediated immune responses directed against both pathogens. Vaccination induced neutralising antibodies capable of inhibiting BoHV-1 and BRSV infection, as well as antigen-specific T-cell responses that mediated cytotoxic activity against target cells expressing either antigen. These findings provide proof-of-concept that chimeric antigens are effective in eliciting humoral and cellular immune response toward two main different pathogens, BoHV-1 and BRSV, and BoHV-4 is a versatile vector for the delivery of heterologous antigens. The demonstrated ability to induce both virus neutralisation and cytotoxic T-cell activity supports the further development of BoHV-4-vectored bivalent vaccines for BRD control, with potential application at improving livestock health and reducing reliance on antimicrobial treatments. Moreover, the present study highlights BoHV-4-based vectors and chimeric peptides as a promising bivalent vaccine platform potentially translatable for controlling similar viruses like human respiratory syncytial virus (hRSV) and varicella zoster virus (VZV) across human populations.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.